BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11509577)

  • 1. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity.
    Hanna IH; Krauser JA; Cai H; Kim MS; Guengerich FP
    J Biol Chem; 2001 Oct; 276(43):39553-61. PubMed ID: 11509577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
    Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
    Hanna IH; Kim MS; Guengerich FP
    Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
    Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
    Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
    Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
    Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.
    Guengerich FP; Johnson WW
    Biochemistry; 1997 Dec; 36(48):14741-50. PubMed ID: 9398194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
    Ueng YF; Kuwabara T; Chun YJ; Guengerich FP
    Biochemistry; 1997 Jan; 36(2):370-81. PubMed ID: 9003190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.
    Smith G; Modi S; Pillai I; Lian LY; Sutcliffe MJ; Pritchard MP; Friedberg T; Roberts GC; Wolf CR
    Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):783-92. PubMed ID: 9560305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates.
    Yamazaki H; Ueng YF; Shimada T; Guengerich FP
    Biochemistry; 1995 Jul; 34(26):8380-9. PubMed ID: 7599128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus).
    Uehara S; Uno Y; Inoue T; Murayama N; Shimizu M; Sasaki E; Yamazaki H
    Drug Metab Dispos; 2015 May; 43(5):735-42. PubMed ID: 25735838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
    Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
    Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
    Uehara S; Uno Y; Hagihira Y; Murayama N; Shimizu M; Inoue T; Sasaki E; Yamazaki H
    Xenobiotica; 2015; 45(9):766-72. PubMed ID: 25801057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of glutathione on the catalytic activity of reconstituted cytochrome P450 3A4.
    Kim BR; Kim DH
    Biochem Biophys Res Commun; 1998 Jan; 242(1):209-12. PubMed ID: 9439637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.
    Pritchard MP; Glancey MJ; Blake JA; Gilham DE; Burchell B; Wolf CR; Friedberg T
    Pharmacogenetics; 1998 Feb; 8(1):33-42. PubMed ID: 9511179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of monomeric reconstituted and membrane microsomal monooxygenase systems of the rabbit liver. I. Properties of NADPH-cytochrome P450 reductase and cytochrome P450 LM2 (2B4) monomers.
    Kanaeva IP; Dedinskii IR; Skotselyas ED; Krainev AG; Guleva IV; Sevryukova IF; Koen YM; Kuznetsova GP; Bachmanova GI; Archakov AI
    Arch Biochem Biophys; 1992 Nov; 298(2):395-402. PubMed ID: 1416970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
    Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
    Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism.
    Li DN; Pritchard MP; Hanlon SP; Burchell B; Wolf CR; Friedberg T
    J Pharmacol Exp Ther; 1999 May; 289(2):661-7. PubMed ID: 10215637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
    Dong MS; Yamazaki H; Guo Z; Guengerich FP
    Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.